The topology of plasminogen binding and activation on the surface of human breast cancer cells by Andronicos, N M & Ranson, M
Overexpression of the components of the plasminogen activation
cascade such as urokinase plasminogen activator (uPA) are associ-
ated with a poor prognosis and a short disease-free period in
patients suffering from breast cancer (reviewed in Duffy et al,
1999; Schmitt et al, 2000). Studies of the plasminogen activation
cascade using human breast cancer cell lines have revealed
insights into this cascade. The metastatic human breast cancer cell
line MDA-MB-231 has a high glu-plasminogen binding capacity
and cell surface uPA antigen levels (Ranson et al, 1998). This
results in the generation of significant amounts of cell-surface-
associated plasmin (Ranson et al, 1998) which facilitates the
degradation of human endothelial basement membranes
(Stonelake et al, 1997). 
Glu-plasminogen binds in a lysine-dependent manner to cells
with low affinity but high capacity (Felez, 1998). Glu-plasminogen
binding to cells is decreased after treatment of the cells with
carboxypeptidase B suggesting that a component of binding is C-
terminal lysine-dependent (Redlitz et al, 1995a). The low affinity
of glu-plasminogen binding has led to suggestions that binding is
not important for activation. However, the fact remains that glu-
plasminogen activation is enhanced in the presence of small lysine
analogues, cells and proteins and that this is attributable to a more
open conformation of glu-plasminogen (Markus, 1996). 
Multiple proteins with glu-plasminogen binding activity have
previously been detected by ligand blots in individual breast
cancer cell lines (Ranson et al, 1998). A heterogeneous group of
cellular plasminogen receptors has been identified and includes;
actin, annexin II, cytokeratin 8, α -enolase, and tetranectin (reviewed
in Felez, 1998). Of these plasminogen receptor candidates only
cytokeratin 8 and α -enolase possess a C-terminal lysine residue.
The other candidates may be considered as latent plasminogen
receptors that require plasmin modification for glu-plasminogen
binding activity. For example, the glu-plasminogen binding
capacity of actin is increased after plasmin modification (Lind and
Smith, 1993). Whilst actin may account for approximately 50% of
the total glu-plasminogen binding capacity of endothelial cells
(Dudani and Gantz, 1996), α -enolase represents only approxi-
mately 10% of the total glu-plasminogen binding capacity of U937
cells (Redlitz et al, 1995b). 
In contrast to glu-plasminogen binding, single- and twin-chain
uPA (sc- and tc-uPA) bind with high affinity to the surfaces of
different cell types (such as cancer cells) via a single receptor desig-
nated as uPAR (Vassalli et al, 1985; Cubellis et al, 1986). Ellis et al
(1999) have demonstrated that glu-plasminogen binds directly to
active site blocked uPA in vitro in a lysine-dependent manner (Kd =
50 nM). Non-active site peptides of uPA containing internal lysine
residues competitively inhibited both glu-plasminogen cell-surface
binding and activation (Ellis et al, 1999). Taken together, this indi-
rectly suggests that cell surface uPA can bind glu-plasminogen via
a non-active site interaction and that such binding is necessary for
cell-surface activation. 
The efficient activation of glu-plasminogen requires both an
activation-susceptible conformation of glu-plasminogen (via
binding) and presence of plasminogen activators. Clearly, a range
of plasminogen receptors, including uPA, may singly or in combi-
nation define the total plasminogen binding capacity of a cell. In
this study we have shown that glu-plasminogen binds in a stable
lysine-dependent manner to breast cancer cells and this results in a
conformational change to the zymogen. Furthermore, we have
characterised the topology of cell surface plasminogen activation
cascade components (glu-plasminogen, uPA, and candidate recep-
tors) responsible for plasmin generation. 
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Summary The urokinase-dependent activation of plasminogen by breast cancer cells plays an important role in metastasis. We have
previously shown that the metastatic breast cancer cell line MDA-MB-231 over-expresses urokinase and binds and efficiently activates
plasminogen at the cell surface compared to non-metastatic cells. The aim of this study was to further characterise plasminogen binding and
determine the topology of cell surface-bound plasminogen in terms of its potential for activation. The lysine-dependent binding of plasminogen
at 4˚C to MDA-MB-231 cells was stable and resulted in an activation-susceptible conformation of plasminogen. Topologically, a fraction of
bound plasminogen was co-localised with urokinase on the surfaces of MDA-MB-231 cells where it could be activated to plasmin. At 37˚C
plasmin was rapidly lost from the cell surface. Apart from actin, other candidate plasminogen receptors were either not expressed or did not
co-localise with plasminogen at the cell surface. Thus, based on co-localisation with urokinase, plasminogen binding is partitioned into two
functional pools on the surface of MDA-MB-231 cells. In conclusion, these results shed further light on the functional organisation of the
plasminogen activation cascade on the surface of a metastatic cancer cell. © 2001 Cancer Research Campaign http://www.bjcancer.com
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Materials 
Goat anti-human annexin II polyclonal antibody and goat anti-
human actin polyclonal antibody were purchased from Santa Cruz
Biotechnology Inc; both antibodies were raised against C-terminal
peptides of their antigens. Mouse anti-human cytokeratin 8 mono-
clonal antibody was purchased from Novocastra Inc. Mouse anti-
human uPA monoclonal antibody (#394; recognises all forms of
human uPA including receptor-bound uPA and B-chain frag-
ment/active mutants) and mouse anti-human uPAR monoclonal
antibody (#3936) were purchased from American Diagnostica
Inc (USA). FITC conjugated sheep anti-goat IgG, Cy3-conjugated
sheep anti-goat IgG, Cy3-conjugated goat anti-mouse IgG,
propidium iodide (PI) and tranexamic acid (TA) were purchased
from Sigma Chemical Co. FITC-conjugated goat anti-mouse IgG
was purchased from Silenus (Australia). Glu-gly-arg chloromethylke-
tone (EGR-CMK) was purchased from Calbiochem (Australia).
Rabbit polyclonal antibody to human recombinant α -enolase was
prepared as described (Andronicos et al, 1997). These antibodies
recognise cellular α -enolase in whole cell lysates (Andronicos et al,
1997) and in fixed, permeabilised breast cancer cell lines (data not
shown). Cy3 and Cy5 were purchased from Amersham Pharmacia
Biotech (Australia). 
Purification and labelling of proteins 
Glu-plasminogen was purified using lysine Sepharose 4B as
described (Andronicos et al, 1997) and FITC-conjugated as
described (Ranson et al, 1998) or Cy5-conjugated according to the
manufacturer’s instructions. The lysine-binding capacity of the
fluorochrome-conjugated glu-plasminogen was verified by lysine
Sepharose affinity chromatography and SDS-PAGE (data not
shown). Bovine aprotinin (Roche Diagnostics) was conjugated
with FITC or Cy5 as described above. Unlabelled and Cy5- or
FITC-labelled aprotinin inhibited plasmin-mediated fibrinogen
proteolysis to similar extents (data not shown). All conjugated
proteins were aliquoted and stored at –70˚C until required. 
Cell culture 
The MCF-7 and MDA-MB-231 human breast cancer cell lines
were routinely cultured as previously described (Ranson et al,
1998). For all experiments cells were cultured for approximately
48 h in either flasks or on coverslips without a change of media.
Unless otherwise specified, all experiments were performed using
MDA-MB-231 cells. 
Flow cytometry and fluorimetry 
Both glu-plasminogen binding and immunocytometry assays were
performed using dual colour flow cytometry with propidium
iodide (PI) to distinguish between viable and non-viable cells as
previously described (Ranson et al, 1998). The stability of glu-
plasminogen or plasmin activity on the surfaces of viable MDA-
MB-231 cells at 37˚C was determined using a modification of the
dual colour flow cytometry method. Briefly, cells were incubated
with either FITC-glu-plasminogen or glu-plasminogen at 4˚C,
washed, and resuspended in binding buffer pre-warmed to 37˚C
for various times. At specific times up to 10 min the reactions
were terminated by adding 50 µ g ml–1 of either aprotinin or FITC-
aprotinin and analysed immediately by dual colour flow cytom-
etry. 
A plasminogen conformational change assay was developed
whereby cells (1 × 106 ml–1) were incubated in black 96-well fluo-
rescence plates (Costar) with FITC-glu-plasminogen (50 µ g ml–1)
in the absence or presence of the tc-uPA specific inhibitor EGR-
CMK (0.5 mM) for 90 min on ice in the dark. The total fluores-
cence of each well was measured at 5 min intervals using a
Biolumin 960 plate reader equipped with a FITC 480/520 excita-
tion/emission filter set. 
Confocal microscopy 
Fixation and quenching of the cells was performed according to
the method of Bastiaens and Jovin (1996). The fixed and quenched
samples were washed twice with PBS, blocked for 1 h with
PBS/0.1% BSA at room temperature and then washed once with
ice-cold PBS/0.1% BSA. The samples were incubated for 1 h on ice
and in the dark with 200 µ l of PBS/0.1% BSA supplemented with
50 µ g ml–1 Cy5-plasminogen. After three 5 min incubations with
1 ml of ice-cold PBS/0.1% BSA, the samples were incubated with
200 µ l of PBS/0.1% BSA containing either 20 µ g ml–1 of a Cy3-
labelled antibody (FRET analysis) or an unlabelled antibody for
30 min on ice and then washed as described above. If an unla-
belled antigen-specific primary antibody was used then the
samples were subsequently incubated on ice with a 1:50 dilution
of a Cy3 secondary antibody for 30 minutes and washed before
mounting. The coverslips were mounted onto microscope slides
using 2 mm wide plastic spacers and 5 µ l of PBS containing 20%
(v/v) glycerol as the mounting medium. 
Fluorescence resonance energy transfer (FRET) experiments
were performed as described by Bastiaens and Jovin (1996).
However, microinjection of labelled protein and permeabilisation
of cells were not required because FRET was used to determine
the proximity of cell surface antigens. 
To determine cell-surface plasmin activity, adherent cells were
washed twice with ice-cold PBS/0.1% BSA and then incubated on
ice for 1 h with 200 µ l PBS/0.1% BSA containing 50 µ g ml–1 of
glu-plasminogen. After two 5 min washes with PBS/0.1% BSA,
the samples were incubated at 10˚C for 5 min in 200 µ l PBS/0.1%
BSA. This relatively gentle activation step was necessary to
prevent the cells detaching from their substrata. The reaction was
stopped by adding Cy5-aprotinin (1 µ M) and incubating for a
further 30 min on ice in the dark. After two 5 min washes with
PBS/0.1%BSA, the samples were fixed and quenched as described
above. The samples were subsequently incubated with uPA mono-
clonal antibody (#394) and the sheep anti-mouse IgG Cy3
secondary antibody as described above. Finally the cells were
mounted and examined by confocal microscopy. 
All confocal microscopy experiments were performed a
minimum of two times and images from a single representative
experiment are shown. All confocal laser scanning microscopy
images were acquired using a Leica TCS SP system fitted with 1.3
NA oil immersion objective lenses. The Cy3 and Cy5 fluorophores
were excited with the 543 nm and 633 nm spectral lines of a He-
Ne laser. The emissions of Cy3 and Cy5 were collected between
560–590 nm and greater than 650 nm, respectively. All images
were analysed using TCS NT software, version 1.6.587 (Leica,
Heidlberg, Germany). 
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Statistical comparisons of the data were made using Student’s t-
test (two-sample assuming unequal variances). 
RESULTS 
Stability and conformation of cell bound plasminogen 
In a previous study we found that even though glu-plasminogen
binds to MDA-MB-231 cells with low affinity but high capacity, the
interaction appeared to be stable under conditions that minimised
activation (Ranson et al, 1998). To examine the lysine-dependent
stability of glu-plasminogen binding to MDA-MB-231 cell
surfaces the TA-dependent association and dissociation phases of
glu-plasminogen binding were compared (Figure 1A). Half-
maximal inhibition of glu-plasminogen association was achieved
with approximately 50 µ M TA, while half-maximal dissociation of
bound glu-plasminogen was achieved with approximately 250 µ M
TA. Furthermore, approximately 25% of bound glu-plasminogen
could not be stripped from the cells, even with 200 mM TA (Figure
1A). In contrast, this concentration of TA competitively inhibited
90% of glu-plasminogen binding. Since glu-plasminogen was
more resistant to TA dissociation than association, this suggested
that a lysine-dependent interaction at the cell surface stabilised the
binding of glu-plasminogen. 
Lysine-dependent conformational differences between free and
cell-bound glu-plasminogen may contribute to the stability of cell
surface-associated glu-plasminogen. Small changes in the total
fluorescence of glu-plasminogen (typically 10%) in the presence
of lysine analogues or proteins are representative of lysine-dependent
conformational changes to the zymogen (Christensen and
Molgaard, 1991; Andronicos et al, 2000). Similarly, the change in
total fluorescence of FITC-glu-plasminogen in the presence of
MDA-MB-231 cells increased to a maximum of approximately
10% in a time-dependent manner (Figure 1B). Furthermore, the
presence of the uPA inhibitor EGR-CMK did not significantly
alter the change in total fluorescence of glu-plasminogen (P >
0.25; Figure 1B), suggesting that the conformational change was
independent of endogenous uPA activity. Taken together, these
results suggest that the binding of glu-plasminogen to the cell
surface may induce a conformational change, which may affect the
stability of bound glu-plasminogen. 
When activation of cell-bound FITC-glu-plasminogen at 37˚C
was terminated at different time points with aprotinin, a maximum
of 40% of the total cell-associated fluorescence was lost from the
surface of MDA-MB-231 cells (Figure 2A). When activation of
cell-bound glu-plasminogen at 37˚C was terminated at different
time points with FITC-aprotinin, a technique that allows the simul-
taneous inhibition and detection of plasmin (Ranson et al, 1998;
O’Mullane and Baker, 1998), approximately 75% of cell-surface
plasmin was lost by 20 min (Figure 2B). In contrast, when activa-
tion was terminated after 5 min with FITC-aprotinin and cells
sampled at various time points after inhibition, no further loss of
plasmin occurred, even after several hours (data not shown). Thus,
it appeared that at 37˚C the turnover of cell surface plasmin(ogen)
was due to proteolysis rather than a non-proteolytic, dissociation
event. 
Candidate cell-surface plasminogen receptor
expression 
The MCF-7 and MDA-MB-231 cell-surface expression levels of
known plasminogen receptor candidates, for which antibodies
were available to us, were examined by dual-colour flow cyto-
metry (Figure 3A). Both of the preformed plasminogen receptors,
α -enolase and cytokeratin 8 antigens, were not detected on the
surfaces of either cell line (Figure 3A). Notably, while both cell
lines expressed comparable levels of cell-surface annexin II (P =
0.32), MCF-7 cells expressed significantly more (4.5 fold) cell-
surface actin (P = 0.019), than did the MDA-MB-231 cells.
Immunohistochemical analysis of fixed, non-permeabilised MDA-
MB-231 and MCF-7 cells visually confirmed these findings (data
Cell surface topology of plasminogen and urokinase 911
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Figure 1 (A) TA competition curves of glu-plasminogen binding to the
MDA-MB-231 cell surface. (   ) The association phase competitive inhibition
of FITC-glu-plasminogen (50 µ gm l –1) binding to MDA-MB-231 cells in the
presence of increasing concentrations of TA. (  ) Competitive dissociation of
FITC-glu-plasminogen bound to MDA-MB-231 cells. Cells were loaded with
FITC-glu-plasminogen (50 µ gm l –1), washed and the bound FITC-
glu-plasminogen dissociated with increasing concentrations of TA. Inset: the
association and dissociation curves for TA concentrations up to 1 mM TA.
Values shown are means ± SEM from 3 separate experiments. *Significantly
different from association (% control) at corresponding concentrations of TA
(P < 0.05). (B) Time course of the change in total fluorescence of FITC-glu-
plasminogen induced by MDA-MB-231 cells at 4˚C in either the presence (  )
or absence ( ) of EGR-CMK. Both curves fitted logarithmic expressions (  ;
r2 = 0.91:  ; r2 = 0.95). Values shown are data from a representative
experiment
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BJOC 01-2022 909-916  10/9/01  2:15 pm  Page 911not shown). Thus, the high and low glu-plasminogen-binding
capacities of the MDA-MB-231 and MCF-7 cell lines, respec-
tively, could not be explained simply by the cell-surface expres-
sion levels of annexin II or actin. 
Relationship between cell-surface uPA expression and
plasminogen-binding capacity 
The high plasminogen-binding MDA-MB-231 cell line expressed
approximately 40- and 20-fold more cell-surface uPA and uPAR,
respectively, than the non-metastatic, low-plasminogen-binding
MCF-7 cell line (Figure 3B). As a direct, non-active site interac-
tion between glu-plasminogen and uPA has been demonstrated by
surface plasmon resonance (Ellis et al, 1999), it seemed possible
that uPA may contribute to the total glu-plasminogen-binding
capacity of the MDA-MB-231 cells. 
To investigate this relationship, the distribution of uPA and glu-
plasminogen were determined by confocal microscopy on fixed
non-permeabilised, adherent MDA-MB-231 cells (Figure 4). MDA-
MB-231 cells were incubated with Cy5-glu-plasminogen (red), then
with an anti-uPA monoclonal antibody and Cy3-conjugated
secondary antibody (green). Urokinase antigen showed a punctate
distribution on the surfaces of the cells (Figure 4D). In contrast,
Cy5-glu-plasminogen was diffusely distributed over the cells, with
areas of high local concentrations at the extremities of most cells
(Figure 4E). As previously shown by ligand histochemistry
(Ranson et al, 1998), Cy5-glu-plasminogen binding was also
lysine-dependent since competition with 5 mM TA inhibited plas-
minogen binding (data not shown). An overlay of the Cy3-uPA
antigen (green) and Cy5-glu-plasminogen (red) images resulted in
defined regions of red and green as well as regions of intense
yellow fluorescence signals on the cell surfaces (Figure 4F). The
presence of yellow fluorescence suggested that glu-plasminogen
and uPA were co-localised at these regions. A three-dimensional
reconstruction of two adherent MDA-MB-231 cells (Figure 4G)
demonstrated that the distribution of co-localised glu-plasminogen
and uPA was on a lateral surface of the cell. 
Bound Cy5-glu-plasminogen did not prevent the uPA mono-
clonal antibody binding to its B-chain epitope (Figure 4), and
pre-incubation with 50 µ gm l –1 of this antibody did not significantly
inhibit the glu-plasminogen binding capacity of MDA-MB-231
cells as assessed by flow cytometry (data not shown). Therefore,
while co-localisation may be due to a direct interaction between
glu-plasminogen  and uPA on the MDA-MB-231 cells, it was
unlikely to be via the active site of uPA. Moreover, maximal plasmin
activity (as detected by Cy5-aprotinin after activation of bound plas-
minogen) corresponded to regions of high uPA antigen concentra-
tions on these cells (data not shown), further suggesting that a
fraction of glu-plasminogen may bind to uPA in a non-active site
manner whereupon it can be activated to plasmin at the cell surface. 
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Figure 2 Loss of bound glu-plasminogen (A) and plasmin activity (B) from
the surfaces of viable MDA-MB-231 cells incubated at 37˚C. Cells were
incubated with 50 µ gm l –1 of either FITC-glu-plasminogen (A) or glu-
plasminogen (B) for 1 h on ice, washed and incubated at 37˚C for various
times. The reactions were terminated with 50 µ gm l –1 of either aprotinin (A) or
FITC-aprotinin (B). All samples were acquired by dual colour flow cytometry
and only PI negative (viable) cell populations were analysed. Values shown
are means of duplicate determinations from a representative experiment 
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Figure 3 Expression of known components of the plasminogen activation
cascade on the surfaces of viable MDA-MB-231 and MCF-7 cells. (A) MDA-
MB-231 ( ) and MCF-7 (  ) cells were probed with antibodies specific for
different known plasminogen receptor candidates or a non-specific primary
antibody and analysed by dual-colour flow cytometry. Non-specific cell-
surface fluorescence was subtracted from all values. Bar heights indicate
means ± SEM of 3 separate experiments. *Significantly different from actin
levels on MDA-MB-231 cells (P < 0.05). (B) MDA-MB-231 or MCF-7 cells
were probed with 20 µ gm l –1 of anti-uPA ( ), anti-uPAR (  ) monoclonal
antibodies or their corresponding isotype control antibodies and analysed by
dual-colour flow cytometry. Isotype-associated fluorescence was subtracted
from all values. Bar heights indicate means ± SEM of 3 separate
experiments. ** Significantly different from values associated with MCF-7
cells (P < 0.021) 
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BJOC 01-2022 909-916  10/9/01  2:15 pm  Page 912The existence of glu-plasminogen-binding sites (red) that did
not co-localise with uPA (green) (Figure 4) indicated that a propor-
tion of the glu-plasminogen bound to the cell surface was due to
the presence of other receptor molecules. 
Relationship between cell-surface annexin II and actin
expression and plasminogen binding 
Confocal microscopy was used to determine whether the cell-
surface plasminogen receptor candidates actin and annexin II
Cell surface topology of plasminogen and urokinase 913
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Figure 4 The co-distribution of uPA and glu-plasminogen on the surfaces of adherent, non-permeabilised MDA-MB-231 cells by confocal microscopy. 
(A, C, and H) Transmission images. (B) IgG1 isotype control antibody. (D and E) The distribution of Cy3-uPA antigen (green) and Cy5-glu-plasminogen (red),
respectively. (F) An overlay of D and E demonstrating the distribution of Cy5-glu-plasminogen (red) and Cy3-uPA antigen (green) on surfaces of MDA-MB-231
cells. (G) A three dimensional reconstruction of two cells demonstrating the distribution of Cy3-uPA antigen (green) and Cy5-glu-plasminogen (red) on the
surfaces of these cells. All fluorescence images are maximum projection composites of at least 8 optical sections. The total depth of the images ranged
between 7.3–12.2 µ m. Scale bars represent 20 µ m
BJOC 01-2022 909-916  10/9/01  2:16 pm  Page 913co-localised with glu-plasminogen and therefore contribute to the
plasminogen-binding capacity of MDA-MB-231 cells (Figure 5).
In contrast to glu-plasminogen, annexin II antigen had a punctate
distribution on the cell surface (Figure 5D). An overlay of the
annexin II antigen (green) and glu-plasminogen (red) images resulted
in well defined, non-overlapping regions of red and green without
any regions of yellow (overlapping) fluorescence (Figure 5F). This
qualitatively suggested that annexin II and glu-plasminogen were not
obviously co-localised on the cell surface. The non-overlap of the
fluorescence emissions from Cy3-annexin II antibody and Cy5-
glu-plasminogen was quantitatively confirmed using fluorescent
energy transfer (FRET) analysis. The apparent FRET efficiency
for the Cy3-Cy5 system on MDA-MB-231 cell surfaces was
approximately 2%, indicating that Cy3-annexin II antibody did not
efficiently donate energy to the Cy5-glu-plasminogen acceptor. 
The distribution pattern of actin antigen was punctate with
regions of high fluorescence at the extremities of the cells (Figure
5H). Most cells contained at least one area of cell-surface actin-
glu-plasminogen co-localisation (Figure 5J; yellow fluorescence).
A three-dimensional reconstruction of optical sections of a cell
probed with Cy5-glu-plasminogen and an actin antibody detected
with Cy3-conjugated secondary antibody demonstrated that glu-
plasminogen was co-localised with actin antigen on a lateral
surface of the cell membrane (Figure 5M). Since MCF-7 cells
express significantly more cell-surface actin but bind significantly
less glu-plasminogen than MDA-MB-231 cells, we investigated
their distribution patterns on fixed, non-permeabilised, adherent
MCF-7 cells. In contrast to MDA-MB-231 cells, there was no co-
localisation (i.e. yellow fluorescence) on the majority of MCF-7
cells (data not shown). Taken together, these data suggest that
actin may also be responsible for binding a fraction of the total
surface localised glu-plasminogen on MDA-MB-231 cells but not
on MCF-7 cells. 
DISCUSSION 
The efficient activation of glu-plasminogen requires both the
activation-susceptible conformation of zymogen and presence of
plasminogen activators. The conformational change of glu-
plasminogen can be mediated by small lysine analogues and α -
enolase (Markus, 1996; Andronicos et al, 2000). Whilst the
binding of glu-plasminogen to cells is low affinity (Felez, 1998;
Ranson et al, 1998) this study demonstrated that binding may also
stabilise an activation-susceptible conformation of glu-plasminogen
on the cell surface. Furthermore, this study mapped the topology
of cell surface-bound glu-plasminogen in terms of its potential for
activation. The results suggest that the fraction of cell-surface-
bound glu-plasminogen that co-localises with uPA may represent
the pool of cell-surface plasminogen that is readily activated. 
The stability of binding on the cell surface was demonstrated by
the fact that it was easier to prevent binding than it was to strip
bound glu-plasminogen with TA. This was accompanied by an
increase in the total fluorescence of FITC-glu-plasminogen (in the
presence or absence of EGR-CMK), suggesting that binding
changes the conformation of glu-plasminogen from the closed to
the more open isomer independent of tc-uPA activity. Thus, MDA-
MB-231 cells may promote the activation of glu-plasminogen by
binding it in a stable, activation-susceptible conformation. 
The second requirement for efficient activation of glu-
plasminogen is access to plasminogen activators. Ellis et al (1999)
previously demonstrated that glu-plasminogen binds to a lysine
residue on the A-chain of cell-surface uPA. In the current study,
bound glu-plasminogen had a uniform cell-surface distribution
whereas the endogenous uPA distribution was punctate. Defined
regions of yellow fluorescence indicated that a proportion of glu-
plasminogen that bound to the MDA-MB-231 cells co-localised
with uPA on the lateral surfaces of these cells. Furthermore, the
uPA/aprotinin (plasmin) distribution patterns suggested that uPA
co-localised glu-plasminogen can be activated at the cell surface.
The anti-uPA antibody used in this study is directed against the B-
chain of uPA and did not inhibit glu-plasminogen binding to the
MDA-MB-231 cells. This suggests that if glu-plasminogen does
bind to uPA directly, then it must be via the A-2 chain and not an
active site-dependent interaction. This would support the indirect
evidence presented by Ellis et al (1999) that glu-plasminogen
binds in a lysine-dependent manner to cell-surface uPA. We are
currently raising antibodies to the peptide corresponding to the
glu-plasminogen-binding site of uPA (Ellis et al 1999) to analyse
the contribution of uPA to the total glu-plasminogen binding
capacity of the MDA-MB-231 cells. Commercially available anti-
bodies raised against the A-chain of uPA have been designed to
block binding to uPAR and would not be useful for the above
purpose. 
At 37˚C both cell-surface-bound glu-plasminogen and plasmin
were rapidly turned over. However, the fact that only 40% of glu-
plasminogen was lost from the cell surface confirms the topolog-
ical data which show that only a fraction of glu-plasminogen
co-localises with uPA where it is activated to plasmin. Once gener-
ated 75% of the plasmin activity was rapidly lost from the surfaces
of viable MDA-MB-231 cells, probably due to plasmin proteo-
lysis. 
Multiple proteins capable of binding glu-plasminogen have
been observed in plasma membrane preparations of MDA-MB-
231 cells (Ranson et al, 1998). These findings as well as the
high number of binding sites for glu-plasminogen per cell
(Ranson et al, 1998) suggest that multiple proteins are respon-
sible for localising glu-plasminogen to the cell surface. The
plasminogen receptors, actin and annexin II were present on the
surfaces of the MDA-MB-231 cells. However, only actin was
co-localised with glu-plasminogen suggesting that actin may
function as a cell-surface plasminogen-binding protein.
Urokinase and actin antigens were also co-localised on the
lateral surfaces of MDA-MB-231 cells (data not shown). This raises
the possibility of a ternary complex between glu-plasminogen, actin
and uPA on the lateral surfaces of viable cells to facilitate
plasmin generation. 
Cell-surface-bound glu-plasminogen exists in two distinct func-
tional pools (activatable and non-activatable) in vitro. The pres-
ence of glu-plasminogen in a non-activatable pool does not
preclude the possibility of activation by stromal plasminogen
activators in vivo (Dano et al, 1999). However, the fact remains
that high tumour cell uPA expression correlates with poor prog-
nosis (reviewed in Duffy et al, 1999; Schmitt et al, 2000). In
conclusion, we have defined three criteria critical for cell-surface
glu-plasminogen activation: (1) glu-plasminogen binding, (2)
lysine-dependent conformational change of glu-plasminogen to
an activation-susceptible form, and (3) co-localisation with uPA.
Satisfaction of all these criteria on the surface of MDA-MB-231
cells facilitates efficient plasmin-mediated pericellular prote-
olysis, which in turn contributes to the invasive and metastatic
capacity of these cells. 
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Figure 5 The co-distribution of glu-plasminogen with annexin II or actin on the surfaces of adherent, non-permeabilised MDA-MB-231 cells by confocal
microscopy. (A, C, G, L and N) Transmission images. (B) Purified, normal goat IgG negative control antibodies. (D and E) The distribution of Cy3-annexin II
antigen (green) and Cy5-glu-plasminogen (red), respectively. (F) An overlay of D and E demonstrating the distribution of both Cy5-glu-plasminogen and Cy3-
annexin II antigen. (H and I) The distribution of Cy3-actin antigen (green) and Cy5-glu-plasminogen (red), respectively. (J) An overlay of H and I demonstrating
the distribution of both Cy5-glu-plasminogen and Cy3-actin antigen. Three-dimensional reconstructions of MDA-MB-231 cells showing the distribution of either
Cy3-annexin II antigen and Cy5-glu-plasminogen (K) or Cy3-actin antigen and Cy5-glu-plasminogen (M) on the surfaces of the cells. All fluorescence images
are maximum projection composites of at least 8 optical sections. The total depth of the images ranged between 6.1–12.2 µ m. Scale bars represent 20 µ m 
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